Giang Son Arrighini

Giang Son Arrighini

Auto-generated profile, based on publicly available information

Giang Son Arrighini

Faculty of Medicine and Surgery, University of Bologna, Bologna, Italy

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 September 2025 in Journal of Clinical Lipidology
Verified
Journal Article
Closed access
VHVinh Q.T. Ho
Vinh Q.T. Ho
NTNghi Bao Tran
Nghi Bao Tran
NNNhan Nguyen
Nhan Nguyen
DDDavid Downes
David Downes
GAGiang Son Arrighini
Giang Son Arrighini
JGJuliana Giorgi
Juliana Giorgi

21 November 2025 in Journal of Interventional Cardiac Electrophysiology
Verified
Journal Article
Open access
PDF file
GAGiang Son Arrighini
Giang Son Arrighini
MDMrunalini Dandamudi
Mrunalini Dandamudi
VHVinh Quang Tri Ho
Vinh Quang Tri Ho
DDDavid Downes
David Downes
NFNicole Felix
Nicole Felix
JGJuliana Giorgi
Juliana Giorgi
Background: Pulsed field ablation (PFA) is a novel, non-thermal technique for atrial fibrillation ablation that is currently under early investigation for paroxysmal supraventricular tachycardia (PSVT). We conducted a meta-analysis to evaluate the efficacy and safety of PFA in this setting. Methods: We systematically searched PubMed, Embase, Cochrane Central, and Web of Science for studies on PFA in PSVT, including atrioventricular nodal reentrant tachycardia (AVNRT) and atrioventricular reentrant tachycardia (AVRT) with concealed or manifest accessory pathways. Outcomes included acute ablation success, success at 1, 3, and 6 months, and procedural/postoperative adverse events (AEs). Proportions were pooled using a random-effects model with arcsine transformation to account for extreme values. Analyses were conducted using R (v4.3.2). Results: Five prospective single-arm studies involving 202 patients were included. The pooled acute success rate was 99.98% (95% CI: 99.29–100), with sustained success at 1, 3, and 6 months. Procedural and postoperative AE rates were low: 0.92% (95% CI: 0.00–4.88) and 0.06% (95% CI: 0.00–0.87), respectively. Subgroup analysis showed 100% acute success in AVNRT and in AVRT with concealed pathways, with high sustained success at 6 months. In AVRT with manifest pathways, acute success was 97.5% (95% CI: 84.74–100), maintained through follow-up. Conclusion: In this systematic review and meta-analysis, PFA demonstrated excellent safety and efficacy for the treatment of PSVT. Randomized controlled trials are warranted to establish the outcomes of PFA in this setting relative to thermal ablation.

13 February 2026 in American Journal of Cardiovascular Drugs
Verified
Journal Article
Open access
PDF file
MDMrunalini Dandamudi
Mrunalini Dandamudi
VHVinh Q. T. Ho
Vinh Q. T. Ho
MSMiguel A. Samaniego-Laguna
Miguel A. Samaniego-Laguna
GAGiang Son Arrighini
Giang Son Arrighini
SCSalomon Chamay
Salomon Chamay
Alejandro N BarbagelataAlejandro N Barbagelata
Alejandro N Barbagelata
Introduction Heart failure (HF), a leading cause of morbidity and mortality worldwide, continues to pose a therapeutic challenge. Nitroxyl (HNO) donors, such as Cimlanod (BMS-986231 or CXL-1427), are emerging as promising agents owing to their unique vasodilatory, inotropic, and lusitropic properties. Purpose This meta-analysis assesses the safety, tolerability, and hemodynamic effects of Cimlanod, in patients with heart failure with reduced ejection fraction (HFrEF). Methods This study consists of four studies, including 459 patients (278 receiving Cimlanod and 181 receiving placebo). The mean age was 63.9 years, 85% were male, and common comorbidities included hypertension (77%) and diabetes (45.7%). Outcomes were evaluated using risk ratios (RR) for binary end points and mean differences (MD) for continuous variables, with 95% confidence intervals (CI) and I2 for heterogeneity. Study quality followed Cochrane methods. Primary outcomes included cardiovascular mortality, hemodynamic measures, and severe adverse events. The protocol was prospectively registered in PROSPERO (CRD420250652675; Feb 2025). Results Cimlanod did not significantly reduce all-cause mortality (RR = 0.96; 95% CI 0.88–1.04; p = 0.15), cardiac death (RR = 0.75; 95% CI 0.37–1.54; p = 0.43), adverse events (RR = 1.51; 95% CI 0.94–2.44; p = 0.073), or serious adverse events (RR = 0.83; 95% CI 0.46–1.48; p = 0.429), when compared with placebo. Although a significantly increased risk of symptomatic hypotension was observed with the use of Cimlanod (RR = 2.22; 95% CI 1.56–3.15; p < 0.01) but no significant effect on systolic or diastolic blood pressure or heart rate was observed in the pooled analyses, whereas significant drop in systolic blood pressure (SBP) (MD − 10.41, 95% CI − 19.89 to − 0.93) was observed with highest dose of Cimlanod i.e. 12 μcg/kg/min. Conclusions Cimlanod did not improve mortality, major hemodynamic end points, or biomarkers and increased the risk of symptomatic hypotension. Although a modest improvement in cardiac index was observed, evidence does not currently support routine clinical use, and further studies are required to identify whether any specific subgroup may benefit. Registration PROSPERO identifier number CRD420250652675.